WCN26-3522 SGLT2 Inhibitor Management and Ketone Monitoring in Critical Care: A Multi-Centre Point Prevalence Study

Read full text Summarise with VIRAT
Authors: Takaya Sasaki, Sharon Micallef, Amanda Y. Wang, Fatima Butt, Naomi E. Hammond, Miranda Hardie, Serena Knowles, Takashi Yokoo, Martin Gallagher
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The use of sodium-glucose co-transporter-2 (SGLT2) inhibitors is growing due to their benefits in chronic kidney disease and heart failure. However, they carry a risk of euglycaemic diabetic ketoacidosis (EDKA), a serious complication. This risk is amplified in the Intensive Care Unit (ICU) setting by prevailing risk factors like fasting and sepsis. Current guidelines recommend temporary cessation of SGLT2 inhibitors in acutely unwell patients, but real-world data on their management and safety monitoring is limited.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Management and Research Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103958–103958
Publication date
25 March 2026
Language
EN